Table 1.
Amino acid variations in E protein among JEV strains.
Fig 1.
Detection of neutralizing antibody titers in pigs and mice vaccinated with the SA14-14-2 vaccine.
(A and B) Pigs (n = 40) were immunized with SA14-14-2 vaccine and serum samples for each animal were collected at 30 days post-vaccination for detection of neutralizing antibodies against SA14-14-2, N28(GIII) and SD12(GI) strains. (A) Seropositive rate against the indicated JEV strains. ***, p < 0.001 detected by Fisher’s exact test. (B) Neutralizing antibody titers (PRNT50) against the indicated JEV strains were measured on BHK-21 cells and plotted. A p value was generated by Student’s t-test. (C, D and E) Mice (n = 10) were immunized with the SA14-14-2 vaccine and serum samples were collected at 14 days post-vaccination for detection of neutralizing antibodies against SA14-14-2 vaccine, N28(GIII) and SD12(GI) strains. (C) PRNT50 titers in serum samples collected from pre-vaccinated mice. (D) PRNT50 titers against the indicated JEV strains in serum samples collected from vaccinated mice. A p value was generated by Student’s t-test. (E) Seropositive rate against the indicated JEV strains. ***, p < 0.001, **, p < 0.01 detected by Fisher’s exact test.
Table 2.
Geometric mean titers (GMT) of PRNT50 titers specific to N28(GIII) and SD12(GI) strains in vaccinated pigs.
Fig 2.
Protective efficacy of the SA14-14-2 vaccine.
Mice (n = 10) were mock-vaccinated (Naïve) or immunized with SA14-14-2 vaccine at high (5000 PFU) dose (A), medium (500 PFU) dose (B), and low (50 PFU) dose and challenged with the indicated JEV strains.
Fig 3.
Protective efficacy of a N28(GIII)-inactivated vaccine.
Mice (n = 10) were mock-vaccinated (Naïve) or immunized with N28(GIII)-inactivated vaccine at high (105 PFU) dose (A), at medium (104 PFU) dose (B and D), and at low (103 PFU) dose (C) and challenged with the indicated JEV strains.
Fig 4.
Protective efficacy of a SD12(GI)-inactivated vaccine.
Mice (n = 10) were mock-vaccinated (Naïve) or immunized with SD12(GI)-inactivated vaccine at high (105 PFU) dose (A), medium (104 PFU) dose (B and D) and low (103 PFU) dose (C), and challenged with the indicated JEV strains.